These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 20063995)

  • 1. One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India.
    Gupta A; Saple DG; Nadkarni G; Shah B; Vaidya S; Hingankar N; Chaturbhuj D; Deshmukh P; Walshe L; Hudelson SE; James M; Paranjape RS; Eshleman SH; Tripathy S
    AIDS Res Hum Retroviruses; 2010 Jan; 26(1):25-31. PubMed ID: 20063995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.
    Gottlieb GS; Badiane NM; Hawes SE; Fortes L; Toure M; Ndour CT; Starling AK; Traore F; Sall F; Wong KG; Cherne SL; Anderson DJ; Dye SA; Smith RA; Mullins JI; Kiviat NB; Sow PS;
    Clin Infect Dis; 2009 Feb; 48(4):476-83. PubMed ID: 19143530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India.
    Saravanan S; Vidya M; Balakrishnan P; Kantor R; Solomon SS; Katzenstein D; Kumarasamy N; Yeptomi T; Sivamalar S; Rifkin S; Mayer KH; Solomon S
    Clin Infect Dis; 2012 Apr; 54(7):995-1000. PubMed ID: 22323567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
    Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
    J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.
    Harrison L; Melvin A; Fiscus S; Saidi Y; Nastouli E; Harper L; Compagnucci A; Babiker A; McKinney R; Gibb D; Tudor-Williams G;
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):42-53. PubMed ID: 26322666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
    Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J;
    Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective treatment of patients in a deep salvage situation with "non-active HAART": experiences with the expert advice system RADATA.
    Lorenzen T; Walther I; Stoehr A; Salzberger B; Plettenberg A;
    Infection; 2009 Dec; 37(6):528-33. PubMed ID: 19826762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.
    Agwu A; Lindsey JC; Ferguson K; Zhang H; Spector S; Rudy BJ; Ray SC; Douglas SD; Flynn PM; Persaud D;
    AIDS Patient Care STDS; 2008 Jul; 22(7):545-52. PubMed ID: 18479228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J;
    HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy.
    Pillay V; Pillay C; Kantor R; Venter F; Levin L; Morris L
    AIDS Res Hum Retroviruses; 2008 Nov; 24(11):1449-54. PubMed ID: 19000027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High level of multidrug resistance mutations in HIV type 1 pol gene and resistance-associated mutations to enfuvirtide (T-20) among antiretroviral-experienced patients from central Brazil.
    Cardoso LP; Stefani MM
    AIDS Res Hum Retroviruses; 2009 Oct; 25(10):943-50. PubMed ID: 19792869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009).
    Parikh UM; Kiepiela P; Ganesh S; Gomez K; Horn S; Eskay K; Kelly C; Mensch B; Gorbach P; Soto-Torres L; Ramjee G; Mellors JW;
    PLoS One; 2013; 8(4):e59787. PubMed ID: 23585827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.
    Johnston V; Cohen K; Wiesner L; Morris L; Ledwaba J; Fielding KL; Charalambous S; Churchyard G; Phillips A; Grant AD
    J Infect Dis; 2014 Mar; 209(5):711-20. PubMed ID: 23943851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chantratita W
    Curr HIV Res; 2008 Sep; 6(5):474-6. PubMed ID: 18855659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral resistance following immunological monitoring in a resource-limited setting of western India: A cross-sectional study.
    Karade SK; Kulkarni SS; Ghate MV; Patil AA; Londhe R; Salvi SP; Kadam DB; Joshi RK; Rewari BB; Gangakhedkar RR
    PLoS One; 2017; 12(8):e0181889. PubMed ID: 28763465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
    Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG
    J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
    ; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
    Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.